« Return to News | Drug Sponsors

Astellas to close Urogenix, shift urology research to Japan

Monday, August 6, 2012 02:09 PM

Astellas Pharma has decided to close Urogenix, an Astellas subsidiary and Durham, N.C.-based research facility focusing on drug discovery in the field of urology.

In March 2006, Astellas acquired this research facility from Dynogen Pharmaceuticals. Since then, Urogenix has evaluated the clinical potential of urological development candidates especially in the area of lower urinary tract disorders. Urology continues to be one of Astellas' five focus therapeutic areas and upon this decision, Astellas will transfer research functions at Urogenix to Astellas' Tsukuba Research Center in Japan.

Urogenix currently employees 13 scientists and staff. The decision to transfer urology research activities to Japan will strengthen the company's commitment to optimizing its research and development resource allocation.

The closure will be completed by the end of December 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.